Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Chakravarty

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Rheumatology (Oxford, England)|April 12, 2021
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysisPhilip J Mease, Iain B McInnes, Lai-Shan Tam, et al.
ACR Open Rheumatology|February 28, 2024
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis RegistryPhilip J Mease, Alexis Ogdie, John Tesser, et al.
ACR Open Rheumatology|October 4, 2024
Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled StudyPhilip J Mease, Xenofon Baraliakos, Vinod Chandran, et al.
Dermatology and Therapy|November 25, 2021
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis RegistryJessica A Walsh, Kristina Callis Duffin, Abby S Van Voorhees, et al.
Annals of the Rheumatic Diseases|September 17, 2025
Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX studyPhilip J Mease, Christopher T Ritchlin, Laura C Coates, et al.
ACR Open Rheumatology|March 7, 2023
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 StudiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 1, 2021
Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic ArthritisIain B McInnes, Proton Rahman, Alice B Gottlieb, et al.
Cancer Immunology, Immunotherapy : CII|June 28, 2019
Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV modelEiichi Ishida, Jina Lee, Jean S Campbell, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 11, 2026
Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE StudyAlexis Ogdie, Joseph F Merola, Philip J Mease, et al.
Rheumatology and Therapy|November 14, 2025
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor InhibitorsPhilip J Mease, Jessica A Walsh, Timothy P Fitzgerald, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Rheumatology (Oxford, England)|April 12, 2021
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysisPhilip J Mease, Iain B McInnes, Lai-Shan Tam, et al.
ACR Open Rheumatology|February 28, 2024
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis RegistryPhilip J Mease, Alexis Ogdie, John Tesser, et al.
ACR Open Rheumatology|October 4, 2024
Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled StudyPhilip J Mease, Xenofon Baraliakos, Vinod Chandran, et al.
Dermatology and Therapy|November 25, 2021
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis RegistryJessica A Walsh, Kristina Callis Duffin, Abby S Van Voorhees, et al.
Annals of the Rheumatic Diseases|September 17, 2025
Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX studyPhilip J Mease, Christopher T Ritchlin, Laura C Coates, et al.
ACR Open Rheumatology|March 7, 2023
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 StudiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 1, 2021
Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic ArthritisIain B McInnes, Proton Rahman, Alice B Gottlieb, et al.
Cancer Immunology, Immunotherapy : CII|June 28, 2019
Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV modelEiichi Ishida, Jina Lee, Jean S Campbell, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 11, 2026
Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE StudyAlexis Ogdie, Joseph F Merola, Philip J Mease, et al.
Rheumatology and Therapy|November 14, 2025
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor InhibitorsPhilip J Mease, Jessica A Walsh, Timothy P Fitzgerald, et al.
Pageof 10